NeueHealth, Inc.
NEUE · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.01 | -0.36 |
| FCF Yield | -205.70% | -4,159.44% | 50.60% | 2.39% |
| EV / EBITDA | -2.80 | -0.62 | -1.70 | -6.57 |
| Quality | ||||
| ROIC | 67.27% | -416.65% | -28.89% | -21.61% |
| Gross Margin | 20.77% | 14.15% | 11.74% | 14.47% |
| Cash Conversion Ratio | 1.24 | 2.37 | -0.17 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.63% | -8.45% | 13.42% | 75.34% |
| Free Cash Flow Growth | 95.40% | -1,418.46% | 300.85% | 181.06% |
| Safety | ||||
| Net Debt / EBITDA | -1.86 | -0.50 | -0.42 | 0.44 |
| Interest Coverage | -5.74 | -15.10 | -28.76 | -47.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.21 | 0.21 | 1.26 |
| Cash Conversion Cycle | -50.00 | 287.82 | 1,799.68 | 223.05 |